Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. (KPTI) reports events occurring on September 17, 2026. The filing details the issuance of a new series of preferred stock to satisfy fees associated with a Forbearance Agreement entered into on September 10, 2026, which was designed to provide the Company additional time to advance its myelofibrosis program, negotiate with lenders, pursue strategic alternatives, or consummate an equity capital raise.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial event disclosed is the settlement of a $20.0 million fee obligation through the issuance of equity rather than cash.
- Fee Obligation Settled: $20.0 million.
- Instrument Issued: 20,000 shares of 0% Series A Convertible Perpetual Preferred Stock.
- Liquidation Preference: $1,000 per share (Total $20.0 million).
- Conversion Price: $1.62 per share of Common Stock.
Material Changes
The Company materially modified the rights of security holders by creating a new class of senior preferred stock. Key changes include:
- Capital Structure: Issuance of 20,000 shares of Convertible Preferred Stock ranking senior to Common Stock regarding dividends and liquidation distributions.
- Conversion Cap: Until stockholder approval is obtained, conversion is limited to an aggregate of 4,520,000 shares of Common Stock (less than 19.99% of outstanding shares). Excess shares are subject to cash settlement based on a 20-trading day volume-weighted average price.
- Accretion: Unpaid cash amounts on the preferred stock accrue interest at 2% per annum, compounded quarterly.
Outlook, Risks, and Contingencies
Management commentary indicates the Company is actively pursuing strategic alternatives and an equity capital raise. The filing highlights several risks and contingencies:
- Stockholder Approval: The Company must seek stockholder consent (the "Consent") to remove the 19.99% conversion cap. A meeting must be held no later than March 15, 2027. If not obtained by then, subsequent meetings will be held until approval is granted.
- Repurchase Rights: Holders have a one-time right to require repurchase at $1,000 per share on or after September 17, 2029. Additionally, holders may demand repurchase upon "Fundamental Changes," including bankruptcy, delisting, or specific FDA actions regarding the Company's myelofibrosis drug application.
- Liquidity Constraints: The Company may not voluntarily enter into transactions resulting in a Fundamental Change unless it has sufficient legally available funds to pay the maximum aggregate repurchase price.
Investor Verification Checklist
- Verify the status of the Forbearance Agreement and ongoing negotiations with lenders.
- Confirm the timeline and outcome of the stockholder meeting required to obtain the "Consent" for full conversion rights (deadline: March 15, 2027).
- Assess the Company's ability to fund potential repurchase obligations under "Fundamental Change" scenarios.
- Monitor progress on the myelofibrosis program and the supplemental new drug application for selinexor in combination with ruxolitinib.
- Review the full text of the Certificate of Designations (Exhibit 3.1) for detailed terms regarding voting rights and protective provisions.